GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » Degree of Operating Leverage

SXTP (60 Degrees Pharmaceuticals) Degree of Operating Leverage : -32.58 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. 60 Degrees Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -32.58. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for 60 Degrees Pharmaceuticals's Degree of Operating Leverage or its related term are showing as below:

SXTP's Degree of Operating Leverage is ranked better than
96.03% of 881 companies
in the Biotechnology industry
Industry Median: -0.02 vs SXTP: -32.58

60 Degrees Pharmaceuticals Degree of Operating Leverage Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Degree of Operating Leverage Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
- -4.16 -1.25 -2.17 3.11

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.42 -0.68 35.81 3.11 -32.58

Competitive Comparison of 60 Degrees Pharmaceuticals's Degree of Operating Leverage

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


60 Degrees Pharmaceuticals's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's Degree of Operating Leverage falls into.


;
;

60 Degrees Pharmaceuticals Degree of Operating Leverage Calculation

60 Degrees Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -10.252 (Mar. 2025) / 0.358 (Mar. 2024) - 1 )/( 0.655 (Mar. 2025) / 0.343 (Mar. 2024) - 1 )
=-29.6369/0.9096
=-32.58***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


60 Degrees Pharmaceuticals  (NAS:SXTP) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


60 Degrees Pharmaceuticals Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Executives
Cheryl Xu director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow director, 10 percent owner, officer: CEO and President 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Charles W Allen director 1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc. 10 percent owner 824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Paul Field director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller officer: Chief Financial Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc. 10 percent owner 200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith officer: Chief Medical Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey director 1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036